Quality of HIV care within the Veterans Affairs health system: A comparison using outcomes from the HIV cost and services utilization study

Journal of Clinical Outcomes Management

Volumn 11, Issue 12, 2004, Pages 765-774

  Korthuis, Philip T ^a   Anaya, Henry D ^b   Bozzette, Samuel A ^c,d   Brinkerhoff, Charles ^a   Mancewicz, Martha ^d   Wang, Mingming ^b   Asch, Steven M ^b,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VA Greater Los Angeles Healthcare   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULIN;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; MYCOBACTERIUM INTRACELLULARE AVIUM; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; QUALITY CONTROL; SCREENING TEST; SEROLOGY; SOLDIER; SYPHILIS; SYPHILIS SEROLOGY; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME; TREPONEMA PALLIDUM; TUBERCULIN TEST;

EID: 14844290254     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13: 1933-42.
3. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated or human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
4. Hecht FM, Wilson IB, Wu AW, et al. Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. Ann Intern Med 1999;131:136-43.
5. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-9.
6. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med 2003;348:2218-27.
7. Anaya HD, Yano EM, Asch SM. Early adoption of human immunodeficiency virus quality improvement in Veterans Affairs medical centers: use of organizational surveys to measure readiness to change and adapt interventions to local priorities. Am J Med Qual 2004;19:137-44.
8. Institute of Medicine of the National Academies. Measuring what matters: allocation, planning, and quality assessment for the Ryan White CARE Act. Available at www.iom.edu/report.asp?id=16325. Accessed 22 Nov 2004.
9. Backus L, Mole L, Chang S, Deyton L. The Immunology Case Registry. J Clin Epidemiol 2001;54 Suppl 1:S12-5.
10. Rubenstein LV, Mittman BS, Yano EM, Mulrow CD. From understanding health care provider behavior to improving health care: The QUERI framework for quality improvement. Quality Enhancement Research Initiative. Med Care 2000;38(6 Suppl 1):I129-41.
11. Demakis JG, McQueen L, Kizer KW, Feussner JR. Quality Enhancement Research Initiative (QUERI): a collaboration between research and clinical practice. Med Care 2000;38 (6 Suppl 1):I17-25.
12. Shapiro MF, Berk ML, Berry SH, et al. National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study. Health Serv Res 1999;34(5 Pt 1):951-68.
13. Frankel MR, Shapiro MF, Duan N, et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999;34(5 Pt 1): 969-92.
14. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999;281:2305-15.
15. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at www.hivatis.org/guidelines/adult/AA_102904.pdf. Accessed 22 Nov 2004.
16. Asch SM, Kerr EA, Hamilton EG, et al, editors. Quality of care for oncologic conditions and HIV: a review of the literature and quality indicators. Available at www.rand.org/publications/MR/MR1281. Accessed 22 Nov 2004.
17. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1-10.
18. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Neyman J, Cam LM, editors. Proceedings of the 5th Berkeley Symposium on Mathematical Statistics and Probability. Berkeley (CA): University of California Press; 1967:221-3.
19. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res 2000;35:389-416.
20. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999;22:369-78.
21. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13:2547-54.
22. Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor use in clinical practice. J Gen Intern Med 1999;14(7):395-401.
23. Korthuis PT, Asch SM, Anaya HD, et al. Lipid screening in HIV-infected veterans. J Acquir Immune Defic Syndr 2004; 35:253-60.
24. Gunn RA, Montes JM, Toomey KE, et al. Syphilis in San Diego County, 1983-1992: crack cocaine, prostitution, and the limitations of partner notification. Sex Transm Dis 1995;22:60-6.
25. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995;142:1255-64.
26. Mathews WC, Barber E. Rising mortality rates among recent entrants to care for HIV infection [abstract]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston, MA. Available at www.hivandhepatitis.com/2003icr/10thretro/main.html. Accessed 22 Nov 2004.
27. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. Adult/Adolescent Spectrum of HIV Disease. J Acquir Immune Defic Syndr 2003;32:499-505.
28. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
29. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel [published erratum appears in JAMA 2003;11:32]. JAMA 2002;288:222-35.
30. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-8.
31. Primary and secondary syphilis - United States, 2002 [published erratum appears in JAMA 2004;291:419]. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2003;52:1117-20.
32. Lopez-Zetina J, Ford W, Weber M, et al. Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6. Sex Transm Infect 2000;76:462-9.
33. Mitka M. US effort to eliminate syphilis moving forward. JAMA 2000;283:1555-6.
34. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
35. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res 1999;34(1 Pt 1):123-44.
36. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 2002;117:231-51.
37. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care 2003;41:1173-82.
38. Kizer KW. The "new VA": a national laboratory for health care quality management. Am J Med Qual 1999;14:3-20.
39. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995;311:793-6.
40. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: measuring quality of care [editorial]. N Engl J Med 1996;335:966-70.
41. OVretveit J, Bate P, Cleary P, et al. Quality collaboratives: lessons from research. Qual Saf Health Care 2002;11:345-51.
42. Mittman BS. Creating the evidence base for quality improvement collaboratives. Ann Intern Med 2004;140:897-901.
43. Demakis JG, Beauchamp C, Cull WL, et al. Improving residents' compliance with standards of ambulatory care: results from the VA Cooperative Study on Computerized Reminders. JAMA 2000;284:1411-6.
44. Safran C, Rind DM, Davis RB, et al. Guidelines for management of HIV infection with computer-based patient's record. Lancet 1995;346:341-6.